logo
Why Krispy Kreme Stock Crashed Again Today

Why Krispy Kreme Stock Crashed Again Today

Yahoo28-02-2025

Shares of Krispy Kreme (NASDAQ: DNUT) continued to sink on Wednesday after dropping by more than 20% on Tuesday. As of 11:50 a.m. ET, the stock was down by about 8.6%.
The doughnut purveyor issued its fourth-quarter report before the opening bell on Tuesday, and on Wednesday morning, multiple Wall Street analysts were issuing downbeat reports and lowering their price targets for its stock. Investing news website The Fly reported that Piper Sandler analyst Brian Mullan cut his price target for the stock by 33% to $12 per share. Morgan Stanley's analysts were more aggressive, slashing their price target in half to just $6 per share.
Krispy Kreme missed expectations on the top and bottom lines in Q4, which was bad enough. But even the high end of management's revenue guidance range for 2025 is modestly lower than it booked in 2024. This goes against what analysts had been expecting. The general notion had been that demand for Krispy Kreme is strong, and that the company's moves to expand distribution would lead to growth. Now, growth is apparently off the table for 2025, so analysts are dialing back their price targets.
If Krispy Kreme's "hot now" donuts ever come to my hometown, I'll be the first in line to buy a dozen, but as much as I love the product, I appreciate investors' current apprehensions about the stock. The company is carrying a heavy debt load and its profit margins are thin, making growth a crucial component of the investment thesis. It has promise, particularly thanks to its growing partnership with McDonald's. But until Krispy Kreme can deliver greater sales growth, its stock will be unlikely to provide any meaningful gains for shareholders.
Before you buy stock in Krispy Kreme, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Krispy Kreme wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $776,055!*
Now, it's worth noting Stock Advisor's total average return is 892% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of February 24, 2025
Jon Quast has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Why Krispy Kreme Stock Crashed Again Today was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders

Business Wire

time8 minutes ago

  • Business Wire

ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Elevation Oncology, Inc. (NASDAQ: ELEV) to Concentra Biosciences, LLC is fair to Elevation shareholders. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing. Halper Sadeh encourages Elevation shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether Elevation and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Elevation shareholders; (2) determine whether Concentra is underpaying for Elevation; and (3) disclose all material information necessary for Elevation shareholders to adequately assess and value the merger consideration. On behalf of Elevation shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Warner Bros. Discovery to split into two media companies
Warner Bros. Discovery to split into two media companies

Yahoo

time17 minutes ago

  • Yahoo

Warner Bros. Discovery to split into two media companies

-- Warner Bros. Discovery (NASDAQ: NASDAQ:WBD) shares paused trading on Monday pending a significant announcement. The company revealed plans to separate into two leading media corporations. The division will result in two distinct entities: Streaming & Studios, and Global Networks. The separation is intended to boost the potential of each business by focusing on their respective strengths. Streaming & Studios will include Warner Bros. Television, Warner Bros. Motion Picture Group, DC Studios, HBO, and HBO Max. This division aims to expand HBO Max, which is slated to enter new markets by 2026, and reach a minimum of $3 billion in yearly adjusted EBITDA. Global Networks will house global entertainment, sports, and news television networks like CNN and TNT Sports in the U.S., along with digital products such as Discovery+ and Bleacher Report. This segment currently reaches over 1.1 billion unique viewers in 200 countries and territories and is known for its high margins and strong free cash flow conversion. David Zaslav will continue as President and CEO of Streaming & Studios, and Gunnar Wiedenfels will become President and CEO of Global Networks. Both will retain their current roles at WBD until the separation is complete. The restructuring is designed to give each company the strategic flexibility needed to compete in the fast-changing media landscape. The Warner Bros. Discovery Board, led by Samuel A. Di Piazza, Jr., believes this transaction will increase shareholder value and is part of their commitment to realizing the full value of the company's assets. Both companies will be well-funded, with Warner Bros. Discovery having initiated tender offers to enhance its debt portfolio, supported by a $17.5 billion bridge facility from J.P. Morgan. Global Networks will retain up to a 20% stake in Streaming & Studios, which it plans to monetize to improve its balance sheet. The separation is expected to be completed by mid-2026, subject to approval by the Warner Bros. Discovery Board, tax rulings, and market conditions. After the announcement, shares rose over 10%. Related articles Warner Bros. Discovery to split into two media companies AppLovin would be more valuable without its 1P games, Morgan Stanley argues Morgan Stanley downgrades Lululemon on weak US growth outlook Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Omada goes public in second recent digital health IPO
Omada goes public in second recent digital health IPO

Yahoo

time17 minutes ago

  • Yahoo

Omada goes public in second recent digital health IPO

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Omada Health went public Friday, marking the second recent digital health IPO after a dry spell for the sector. The digital chronic condition management company opened at $23 per share, a 21% bump over its public offering price of $19 per share. Omada's debut comes on the heels of virtual musculoskeletal company Hinge Health's IPO last month. 'I think it is definitely a promising bellwether for the industry,' John Beadle, co-founder and managing partner of Aegis Ventures, told Healthcare Dive. Omada, which was founded in 2011 and has raised hundreds of millions of dollars in venture capital funding, offers digital management programs for conditions like diabetes, obesity and hypertension. Care teams also work with patients to build treatment plans and equip users with connected devices like blood pressure cuffs or digital scales. The company filed to go public in May. Now, Omada is trading on Nasdaq under the ticker symbol 'OMDA,' having raised $150 million in its IPO. The firm's public offering price of $19 was at the midpoint of the expected range it released Thursday. Omada's IPO comes as the digital health sector has seen few public offerings in recent years. A surge of companies notched public exits in 2021, but the number has declined significantly in recent years. Many digital health companies that went public during the boom — particularly ones that used mergers with special purpose acquisition companies — performed poorly, and may have been better off as strategic M&A targets, Beadle said. However, the industry seemed poised for more companies to make the leap this year, and their performance could push others to follow in their footsteps, experts told Healthcare Dive late last year. Now, two digital health companies have gone public in recent weeks. Hinge debuted on the New York Stock Exchange in May, opening 23% above its public offering price. Still, the sector isn't seeing a flood of digital health companies moving to go public like in 2021, Beadle said. 'I don't think there's that many companies that are ready and have the operational maturity, growth trajectory [and] outcomes that Hinge and Omada do,' he said. 'But I think both companies were exceptionally well prepared to do well when they went public.' Though Hinge had given back most of its early post-IPO gains by the time of Omada's pricing, its performance still provided a 'good tailwind' for the chronic conditions management firm, Edward Best, co-chair of the capital markets practice at Willkie Farr & Gallagher, said via email. Still, larger macroeconomic conditions will also impact whether more digital health companies decide to make the leap to the public markets. Some technology companies decided to delay their IPOs this spring after tariffs announced by President Donald Trump roiled the markets. Stability is key to the IPO market, as investors will likely choose safer investments during periods of volatility, Best said. Companies need to think about their own operations and readiness to go public as well as broader conditions. 'The IPO market has periods when the window is more open than others. A company that is ready and wants or needs to go public when the window is open should certainly take a long hard look within,' he said. 'Waiting too long could mean missing the window.' Recommended Reading Hinge Health goes public in positive signal for digital health IPOs

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store